pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Keytruda · news · pharmadog
← back to Keytruda
News mentioning Keytruda
114
stories
2d
Merck's top dealmaker signals more M&A as Keytruda's patent cliff nears
endpoints
2d
Summit, Akeso’s ivonescimab bests Merck’s Keytruda in China trial—again
biospace
2d
Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharma dive
3d
Novartis inks $3.2B subcutaneous drug delivery deal with Alteogen
fiercebiotech
3d
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
8d
BioNTech halts mid-stage trial of personalized mRNA vaccine in colorectal cancer
biospace
8d
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
fiercebiotech
9d
Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say
biopharma dive
9d
What’s in Merck and Moderna’s cancer vaccine algorithm?
stat
10d
Summit, Akeso tout biliary cancer win for PD-1/VEGF in China—but details are pending
biospace
10d
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
fiercebiotech
10d
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
biospace
11d
With mRNA back in the spotlight, tRNA shows potential to treat genetic disease
fiercebiotech
11d
How Trump’s cuts are reshaping America’s health system
stat
16d
Cancer vaccine win restores Wall Street’s faith in Moderna
biopharma dive
16d
Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
biospace
16d
Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
fiercebiotech
17d
Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
biospace
17d
Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal
biospace
17d
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
biopharma dive
17d
STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
stat
17d
Merck, Moderna’s personalized cancer vaccine slows recurrence in phase 3, setting up approval push
fiercebiotech
18d
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
biospace
18d
Regeneron ends eye disease study due to antibody's safety profile
biospace
18d
Regeneron ends eye disease study due to antibody's safety profile
biospace
19d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
19d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
19d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
19d
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
23d
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
fiercebiotech
← prev
page 1 of 4
next →
